GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies.

[featured_image]

Download

Version
Download 681
File Size 0.00 KB
File Count 1
Create Date August 27, 2020
Last Updated December 15, 2022

GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies.

Attached Files

File	Action
	Download

By Michael Foley|2022-12-15T14:53:55+00:00August 27, 2020|Comments Off

About the Author: Michael Foley

National Tay-Sachs & Allied Diseases Association (NTSAD) leads the worldwide fight to treat and cure Tay-Sachs, Canavan, GM1, and Sandhoff diseases by driving research, forging collaboration, and fostering community. Supporting families is the center of everything we do.

The content of this website is intended for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment.

The National Tay-Sachs & Allied Diseases Association (NTSAD) leads the worldwide fight to treat and cure Tay-Sachs, Canavan, GM1, and Sandhoff diseases by driving research, forging collaboration, and fostering community. Supporting families is the center of everything we do.

Community News

Get the latest news from NTSAD about our Community, the research that provides hope, and what is happening in the world of rare disease.

2001 Beacon Street, Suite 204
Boston, MA 02135
(617) 277-4463
info@ntsad.org

Tax ID
#13-1912877

National Tay-Sachs & Allied Diseases Association
2001 Beacon Street, Suite 204, Boston, MA 02135
(617) 277-4463 | info@ntsad.org

Tax ID
#13-1912877

GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies.

GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies.

Attached Files

Share This Story, Choose Your Platform!

About the Author: Michael Foley

Community News

Your Feedback